Abcam, ab232330, Anti-TXNIP antibody [EPR14774] - Mouse IgG2b (Chimeric) - BSA and Azide free

Size: 100µg / 1mg
Mouse Recombinant Monoclonal TXNIP antibody. Carrier free. Suitable for IHC-P, WB, ICC/IF, Flow Cyt (Intra) and reacts with Mouse, Human, Rat samples. Cited in 3 publications.
Key facts
Host species:Mouse,
Clonality:Monoclonal,
Clone number:EPR14774,
Isotype:IgG,
Light chain type:kappa,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:Flow Cyt (Intra), ICC/IF, IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab232330 is the carrier-free version of
ab210826
This mouse monoclonal chimeric antibody has been engineered from a RabMAb parent antibody (
ab188865
). By necessity, some rabbit sequence is retained as part of the variable domain. When multiplexing with other rabbit-derived antibodies, using cross absorbed Fc-reactive secondary antibodies are recommended.
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TXNIP also known as thioredoxin-interacting protein or VDUP1 is an inhibitory protein that binds to and regulates the activity of thioredoxin. It has a molecular mass of around 46 kDa. TXNIP is expressed in various tissues including heart liver and skeletal muscle. It acts to control intracellular redox states by modulating thioredoxin’s antioxidant functions. TXNIP expression can vary according to oxidative stress and cellular metabolic conditions.
Biological function summary
TXNIP regulates cellular processes such as glucose metabolism stress response and apoptosis. It does not form a complex but functions by negatively regulating the activity of thioredoxin. This protein can lead to increased reactive oxygen species (ROS) when it inhibits thioredoxin influencing cellular redox balance. TXNIP therefore plays a regulatory role in metabolic pathways and cellular stress responses by modulating thioredoxin activity and ROS levels.
Pathways
TXNIP is a significant component of the oxidative stress and glucose metabolism pathways. In the oxidative stress pathway TXNIP interacts with thioredoxin influencing ROS detoxification and redox-sensitive signaling. In glucose metabolism TXNIP can affect insulin signaling by interacting with glucose transporter-1 (GLUT1). These interactions highlight TXNIP's regulatory role in cellular metabolism and stress-related signaling making it a node of convergence with proteins like thioredoxin and GLUT1.
TXNIP levels have been implicated in conditions such as type 2 diabetes and cardiovascular diseases. Elevated TXNIP expression has been observed in insulin resistance where it affects glucose uptake by modifying GLUT1 activity and links to thioredoxin in cardiovascular tissues resulting in oxidative stress damage. These connections position TXNIP as a potential therapeutic target for managing metabolic disorders and cardiovascular complications.